Marex Group’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-25,000
Closed -$223 – 1780
2026
Q2
$223 Hold
25,000
– – ﹤0.01% 1116
2026
Q1
$250 Hold
25,000
– – ﹤0.01% 1004
2025
Q4
$345 Hold
25,000
– – ﹤0.01% 961
2025
Q3
$423 Hold
25,000
– – ﹤0.01% 838
2025
Q2
$388 Hold
25,000
– – ﹤0.01% 641
2025
Q1
$460 Hold
25,000
– – ﹤0.01% 682
2024
Q4
$925 Hold
25,000
– – ﹤0.01% 675
2024
Q3
$873 Hold
25,000
– – ﹤0.01% 604
2024
Q2
$275 Hold
25,000
– – ﹤0.01% 635
2024
Q1
$308 Hold
25,000
– – ﹤0.01% 478
2023
Q4
$450 Buy
+25,000
New +$300 ﹤0.01% 560

Marex Group's KTTAW Position: Q3 2026 in Review

Marex Group sold out of Pasithea Therapeutics Warrants (KTTAW) in Q3 2026, closing a stake of 25,000 shares — an estimated $223 sold.

Marex Group first reported a position in KTTAW in Q4 2023 and held it in 11 quarters. The position peaked at $925 in Q4 2024. 0 funds tracked by Wall St. Rank hold KTTAW as of Q3 2026.

  • Marex Group reported no remaining Pasithea Therapeutics Warrants position as of Q3 2026 after selling out during the quarter.
  • Marex Group sold 25,000 Pasithea Therapeutics Warrants shares in Q3 2026, an estimated $223.
  • Marex Group first reported a position in Pasithea Therapeutics Warrants in Q4 2023 and held it in 11 quarters.
  • Marex Group's Pasithea Therapeutics Warrants position peaked at $925 in Q4 2024.
  • 0 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q3 2026.

Based on Marex Group's 13F filing for Q3 2026, filed 16 Nov 2026.